I-Mab’s innovative pipeline is driven by internal R&D’s Fast-to-Proof-of-Concept, Fast-to-Market development strategies, and through global partnerships. Founded in 2016, the company has offices in the USA and China.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze